The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Consensus Conference

[1]  S. Mayer,et al.  Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage , 2007, Stroke.

[2]  D. Adams,et al.  Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. , 2006, The Annals of thoracic surgery.

[3]  D. Story,et al.  Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[4]  Rolf Rossaint,et al.  Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective , 2006, Critical care.

[5]  Keyvan Karkouti,et al.  Prediction of massive blood transfusion in cardiac surgery , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[6]  W. Beattie,et al.  Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[7]  W. Beattie,et al.  The effects of a treatment protocol for cardiac surgical patients with excessive blood loss on clinical outcomes , 2006, Vox sanguinis.

[8]  Andrew D. Rosenberg,et al.  Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on perioperative blood transfusion and adjuvant therapies , 2006 .

[9]  J. Ingerslev,et al.  Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  T. Brott,et al.  Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile , 2006, Transfusion.

[11]  G. Gensini,et al.  Small-Dose Recombinant Activated Factor VII (NovoSeven®) in Cardiac Surgery , 2006, Anesthesia and analgesia.

[12]  Jenifer Ballen,et al.  Dissection aortique et asystolie sous hypothermie chez un Témoin de Jéhovah : un cas pour le facteur VIIa recombinant ? , 2006 .

[13]  B. Muirhead,et al.  Aortic dissection and hypothermic arrest in a Jehovah’s Witness patient: a case for recombinant factor VIIa? , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[14]  A. Tuckfield,et al.  Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. , 2006, The Annals of thoracic surgery.

[15]  Keyvan Karkouti,et al.  A propensity score case‐control comparison of aprotinin and tranexamic acid in high‐transfusion‐risk cardiac surgery , 2006, Transfusion.

[16]  J. Fraser,et al.  The Use of Recombinant Activated Factor VII for Refractory Bleeding Post Complex Cardiothoracic Surgery , 2006, Anaesthesia and intensive care.

[17]  Po-Huang Lee,et al.  Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, American journal of surgery.

[18]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[19]  J. Hanley,et al.  Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: use of a clinical scoring system to predict outcome , 2006, Vox sanguinis.

[20]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[21]  D. O'shaughnessy,et al.  Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. , 2005, British journal of anaesthesia.

[22]  K. Wernecke,et al.  Recombinant activated factor VII for refractory bleeding after cardiac surgery—A retrospective analysis of safety and efficacy , 2005, Critical Care Medicine.

[23]  J. Szer,et al.  Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation , 2005, Journal of thrombosis and haemostasis : JTH.

[24]  J. García-Valdecasas,et al.  Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  A. Jeppsson,et al.  Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[26]  G. Klintmalm,et al.  Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[27]  P. Thorborg,et al.  Emerging off-label uses for recombinant activated factor VII: grading the evidence. , 2005, Critical care clinics.

[28]  R. Suojaranta-Ylinen,et al.  Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. , 2005, The Annals of thoracic surgery.

[29]  R. Rossaint,et al.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. , 2005, The Journal of trauma.

[30]  R. Grounds,et al.  Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. , 2005, British journal of anaesthesia.

[31]  Howard K. Song,et al.  Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. , 2005, The Annals of thoracic surgery.

[32]  M. Michaelson,et al.  Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force , 2005, Journal of thrombosis and haemostasis : JTH.

[33]  W. Bechstein,et al.  Recombinant Coagulation Factor VIIa in Major Liver Resection: A Randomized, Placebo-controlled, Double-blind Clinical Trial , 2005, Anesthesiology.

[34]  S. McCluskey,et al.  Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case‐control analysis , 2005, Transfusion.

[35]  Dougald M Monroe,et al.  The use of recombinant factor VIIa in the treatment of bleeding disorders. , 2004, Blood.

[36]  A. Aggarwal,et al.  Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage , 2004, Thrombosis journal.

[37]  D. Thabut,et al.  Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. , 2004, Gastroenterology.

[38]  S. McCluskey,et al.  The independent association of massive blood loss with mortality in cardiac surgery , 2004, Transfusion.

[39]  C. Eby,et al.  Transfusion medicine service policies for recombinant factor VIIa administration , 2004, Transfusion.

[40]  M. Herbertson.  Recombinant activated factor VII in cardiac surgery , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[41]  R. Damiano,et al.  Multivariate analysis of risk factors for deep and superficial sternal infection after coronary artery bypass grafting at a tertiary care medical center. , 2004, Seminars in thoracic and cardiovascular surgery.

[42]  R. Tait,et al.  ‘Last‐ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective , 2004, Vox sanguinis.

[43]  U. Hedner.  Dosing with recombinant factor viia based on current evidence. , 2004, Seminars in hematology.

[44]  Dougald M Monroe,et al.  Safety profile of recombinant factor VIIa. , 2004, Seminars in hematology.

[45]  J. Egan,et al.  Recombinant activated factor VII in paediatric cardiac surgery , 2004, Intensive Care Medicine.

[46]  J. Eikelboom,et al.  Recombinant activated factor VII for the treatment of life-threatening haemorrhage , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[47]  K. Kurth,et al.  Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial , 2003, The Lancet.

[48]  M. Al Douri,et al.  Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[49]  A D Shapiro,et al.  Recombinant Factor VIIa in the Treatment of Bleeding in Hemophilic Children with Inhibitors , 2000, Seminars in thrombosis and hemostasis.

[50]  J L Cox,et al.  Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. , 1996, The Journal of thoracic and cardiovascular surgery.

[51]  T. Treasure,et al.  Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. , 1995, The Annals of thoracic surgery.

[52]  W. T. Sawyer,et al.  Pharmacokinetics and pharmacodynamics of recombinant factor VIIa , 1994, Clinical pharmacology and therapeutics.